1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).
Non Hodgkin Lymphoma|Follicular Lymphoma|Indolent Lymphoma|B-cell Lymphoma|Transformed Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma
DRUG: Zydelig
Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year, The proportion of patients who discontinued the study due to Zydelig-related adverse events., 1 year.
Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation., 1- and 2-year Progression-free survival; Progression-free survival is defined as time from the date of autologous stem cell transplantation to progression, relapse and death, whichever comes first., 1- and 2-year Progression-free survival
This pilot study is focused on maintenance Zydelig for patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL) after autologous stem cell transplantation. Oral Zydelig at 150 mg (or adjusted dose) twice daily continuously on 28-day cycles. Patients will continue on Zydelig up to one year or to progression/relapse/death or unacceptable toxicity, whichever occurs first.